Team
Julie Guillermet-Guibert

SigDYN :

Integrated cellular signalling and PI3K isoforms

the specifities

of our research axis

 

The team directed by J Guillermet-Guibert studies the family of lipid kinases known as phosphoinositide 3-kinases (PI3Ks) from different angles. This family of enzymes is involved in major cellular functions such as cell survival, proliferation, growth, migration, differentiation but also protein synthesis and intracellular vesicular trafficking. In vertebrates, the PI3K family is divided into three different classes. This classification is based on their structure, mode of activation and lipid substrate specificity in vitro and in vivo. These enzymes, encoded by 8 different genes, all phosphorylate the hydroxyl group in position 3 of the inositol ring of phosphoinositides, hence their name.

Only class I (composed of PI3Kα, PI3Kβ, PI3Kγ, PI3Kδ) can convert phosphatidylinositol (4,5)-bisphosphate [PtdIns-4,5-P2, PtdIns (4,5) P2, PIP2] to phosphatidylinositol (3,4,5)-trisphosphate [PtdIns-3,4,5-P3, PtdIns (3,4,5) P3, PIP3]. The substrate of class I enzymes is mainly located at the cell membrane. Thus, activation of class I PI3Ks produces a lipid second messenger at the plasma membrane at the interface with the cytoplasm, which allows the transmission of biochemical information into the cytoplasm and leads to a cellular response.

Class II (PI3KC2α, PI3KC2β, PI3KC2γ) and class III (VPS34) PI3Ks can generate phosphatidylinositol 3-phosphate [PtdIns-3-P, PtdIns (3) P, PI-3-P]. Class II PI3Ks can also synthesise phosphatidylinositol (3,4)-bisphosphate [PtdIns-3, 4-P2, PtdIns (3,4) P2]. The substrates of these enzymes are present in the outer membranes of organelles within the cell, at the level of endosomes, autophagosomes. Thus, class II and III PI3Ks control intracellular vesicular trafficking.

The high activation of class I PI3Ks is considered to be a characteristic of cancer; however, the role of each class I PI3K in the different stages of carcinogenesis is poorly understood. This research is carried out by our team.

The roles of class II and III PI3Ks in cancer are poorly studied. We have undertaken to understand them.

We mostly apply our research to solid cancers such as pancreatic cancer to better understand, earlier diagnose and treat this deadly disease. We also work on ovarian cancers and collaborate with teams working on liquid cancers.

 

Oncogenic signalling

PI3K

Targeted therapies

résistance

Tumour niche

Cancer initiation

Mechanobiology

compression

Genetically modified mice

Tumour imaging

Pancreatic cancer

Ovarian cancer

RESEARCH PROJECTS

THE TEAM’S
FOCUS

Discover

New publication on Autophagy

Read More

Focus research 2022 SigDyn team

Read More

Cancer under pressure: which signals are activated?

Read More

How to target PI3Ks 3 classes in cancer?

Read More

The cell signalling enzymes PI3Kalpha and PI3Kβ play major roles in the body.

Read More

Understand

On the occasion of the World Cancer Day, digital round table “Toulouse: innovation in oncology (in french)

Read More

Participate

TOW2025 J-30 Earlybird registration

Read More

CRCT@EACR2024-session Mitochondria & Cancer, two CRCT team present

Read More

Image CRCT Laureate of the prestigious CNRS LLPI competition

Read More

CNRS ApiPhot Technology School – Focus on depth and super-resolution microscopy

Read More

WORKSHOP : Clinical applications of PI3K inhibitors

Read More

En live

Guillermet's Lab Follow 151 134

Julie Guillermet-Guibert's lab located in https://t.co/Y4Z7QkJ9AU, working on signaling dynamics and focusing on PI3K in pancreatic cancer.

GuillermetLab
Voir plus

SCIENTIFIC PRODUCTIONS

PUBLICATIONS 2024
Despas, Fabien, Maria Chaouki, Sandra De Barros, Baptiste Bonneau, Ben Allal, Julie Guillermet-Guibert, and Loïc Ysebaert. “Pharmacokinetics of Idelalisib in Chronic Lymphocytic Leukemia and Follicular Lymphoma Disclose Better Outcomes for Patients with Lower Exposure.” Leukemia & Lymphoma, May 15, 2024, 1–3. https://doi.org/10.1080/10428194.2024.2353330.
Fébrissy, Chanaëlle, Marine Adlanmerini, Christel Péqueux, Frédéric Boudou, Mélissa Buscato, Adrien Gargaros, Silveric Gilardi-Bresson, et al. “Reprogramming of Endothelial Gene Expression by Tamoxifen Inhibits Angiogenesis and ERα-Negative Tumor Growth.” Theranostics 14, no. 1 (2024): 249–64. https://doi.org/10.7150/thno.87306.
PUBLICATIONS 2023
Schmitter, Céline, Mickaël Di-Luoffo, and Julie Guillermet-Guibert. “Transducing Compressive Forces into Cellular Outputs in Cancer and Beyond.” Life Science Alliance 6, no. 9 (September 2023): e202201862. https://doi.org/10.26508/lsa.202201862.
Nicco, Carole, Marine Thomas, Julie Guillermet, Maryline Havard, Fanny Laurent-Tchenio, Ludivine Doridot, François Dautry, Frédéric Batteux, and Thierry Tchenio. “Mechanistic Target of Rapamycin (MTOR) Regulates Self-Sustained Quiescence, Tumor Indolence, and Late Clinical Metastasis in a Beclin-1-Dependent Manner.” Cell Cycle (Georgetown, Tex.) 22, no. 5 (March 2023): 542–64. https://doi.org/10.1080/15384101.2022.2123187.
Thibault, Benoît, Fernanda Ramos-Delgado, and Julie Guillermet-Guibert. “Targeting Class I-II-III PI3Ks in Cancer Therapy: Recent Advances in Tumor Biology and Preclinical Research.” Cancers 15, no. 3 (January 27, 2023): 784. https://doi.org/10.3390/cancers15030784.
Ben Meriem, Zacchari, Tiphaine Mateo, Julien Faccini, Céline Denais, Romane Dusfour-Castan, Catherine Guynet, Tatiana Merle, et al. “A Microfluidic Mechano-Chemostat for Tissues and Organisms Reveals That Confined Growth Is Accompanied with Increased Macromolecular Crowding.” Lab on a Chip 23, no. 20 (2023): 4445–55. https://doi.org/10.1039/D3LC00313B.
PUBLICATIONS 2022
Chaves-Almagro, Carline, Johanna Auriau, Alizée Dortignac, Pascal Clerc, Hubert Lulka, Simon Deleruyelle, Fabrice Projetti, et al. “Upregulated Apelin Signaling in Pancreatic Cancer Activates Oncogenic Signaling Pathways to Promote Tumor Development.” International Journal of Molecular Sciences 23, no. 18 (September 13, 2022): 10600. https://doi.org/10.3390/ijms231810600.
PUBLICATIONS 2021
Cintas, Célia, Thibault Douche, Zahra Dantes, Emmanuelle Mouton-Barbosa, Marie-Pierre Bousquet, Coralie Cayron, Nicole Therville, et al. “Phosphoproteomics Identifies PI3K Inhibitor-Selective Adaptive Responses in Pancreatic Cancer Cell Therapy and Resistance.” Molecular Cancer Therapeutics 20, no. 12 (December 2021): 2433–45. https://doi.org/10.1158/1535-7163.MCT-20-0981.
Di-Luoffo, M., Z. Ben-Meriem, P. Lefebvre, M. Delarue, and J. Guillermet-Guibert. “PI3K Functions as a Hub in Mechanotransduction.” Trends in Biochemical Sciences 46, no. 11 (November 2021): 878–88. https://doi.org/10.1016/j.tibs.2021.05.005.
Cayron, C., S. Rigal, and J. Guillermet-Guibert. “Is Targeting Autophagy a Promising Lead to Unveil the Cloak of Invisibility in Pancreatic Cancer?” Clinics and Research in Hepatology and Gastroenterology 45, no. 6 (November 2021): 101622. https://doi.org/10.1016/j.clinre.2021.101622.
Thibault, Benoit, Fernanda Ramos-Delgado, Elvire Pons-Tostivint, Nicole Therville, Celia Cintas, Silvia Arcucci, Stephanie Cassant-Sourdy, et al. “Pancreatic Cancer Intrinsic PI3Kα Activity Accelerates Metastasis and Rewires Macrophage Component.” EMBO Molecular Medicine 13, no. 7 (July 7, 2021): e13502. https://doi.org/10.15252/emmm.202013502.
Arcucci, Silvia, Fernanda Ramos-Delgado, Coralie Cayron, Nicole Therville, Marie-Pierre Gratacap, Céline Basset, Benoit Thibault, and Julie Guillermet-Guibert. “Organismal Roles for the PI3Kα and β Isoforms: Their Specificity, Redundancy or Cooperation Is Context-Dependent.” The Biochemical Journal 478, no. 6 (March 26, 2021): 1199–1225. https://doi.org/10.1042/BCJ20210004.
Mazloumi Gavgani, Fatemeh, Thomas Karlsson, Ingvild L. Tangen, Andrea Papdiné Morovicz, Victoria Smith Arnesen, Diana C. Turcu, Sandra Ninzima, et al. “Nuclear Upregulation of Class I Phosphoinositide 3-Kinase P110β Correlates with High 47S RRNA Levels in Cancer Cells.” Journal of Cell Science 134, no. 3 (February 10, 2021). https://doi.org/10.1242/jcs.246090.
PUBLICATIONS 2020
Rizzuti, Ilaria Francesca, Pietro Mascheroni, Silvia Arcucci, Zacchari Ben-Mériem, Audrey Prunet, Catherine Barentin, Charlotte Rivière, et al. “Mechanical Control of Cell Proliferation Increases Resistance to Chemotherapeutic Agents.” Physical Review Letters 125, no. 12 (September 18, 2020): 128103. https://doi.org/10.1103/PhysRevLett.125.128103.
Hakobyan, Davit, Chantal Médina, Nathalie Dusserre, Marie-Laure Stachowicz, Charles Handschin, Jean-Christophe Fricain, Julie Guillermet-Guibert, and Hugo Oliveira. “Laser-Assisted 3D Bioprinting of Exocrine Pancreas Spheroid Models for Cancer Initiation Study.” Biofabrication 12, no. 3 (April 16, 2020): 035001. https://doi.org/10.1088/1758-5090/ab7cb8.
Cayron, Coralie, and Julie Guillermet-Guibert. “The Type of KRAS Mutation Drives PI3Kα/γ Signalling Dependency: Implication for the Choice of Targeted Therapy in Pancreatic Adenocarcinoma Patients.” Clinics and Research in Hepatology and Gastroenterology, 2020, S2210740120301662. https://doi.org/10.1016/j.clinre.2020.05.021.
PUBLICATIONS 2019
Zamora, Audrey, Melinda Alves, Charlotte Chollet, Nicole Therville, Tiffany Fougeray, Florence Tatin, Camille Franchet, et al. “Paclitaxel Induces Lymphatic Endothelial Cells Autophagy to Promote Metastasis.” Cell Death & Disease 10, no. 12 (December 20, 2019): 956. https://doi.org/10.1038/s41419-019-2181-1.
Müller, David, Sauyeun Shin, Théo Goullet de Rugy, Rémi Samain, Romain Baer, Manon Strehaiano, Laia Masvidal-Sanz, et al. “EIF4A Inhibition Circumvents Uncontrolled DNA Replication Mediated by 4E-BP1 Loss in Pancreatic Cancer.” JCI Insight 4, no. 21 (November 1, 2019). https://doi.org/10.1172/jci.insight.121951.
Therville, Nicole, Silvia Arcucci, Aurélie Vertut, Fernanda Ramos-Delgado, Dina Ferreira Da Mota, Marlène Dufresne, Céline Basset, and Julie Guillermet-Guibert. “Experimental Pancreatic Cancer Develops in Soft Pancreas: Novel Leads for an Individualized Diagnosis by Ultrafast Elasticity Imaging.” Theranostics 9, no. 22 (2019): 6369–79. https://doi.org/10.7150/thno.34066.

team members

Corentin Bouvier
Doctorant / PhD student
Silvia Arcucci
Ingénieur de laboratoire / laboratory engineer
Romina D'ANGELO
Ingénieur de laboratoire / laboratory engineer
Sanzhar Aitbay
Doctorant / PhD student
Maria Chaouki
Doctorant / PhD student
Julien Faccini
Ingénieur de laboratoire / laboratory engineer
Hala Shalhoub
Chercheur Post-Doctorant / Post-Doc researcher
Julie Guillermet-Guibert
Chercheur statutaire / permanent scientist
Nicole Therville
Ingénieur de laboratoire / laboratory engineer
Benoît Thibault
Chercheur statutaire / permanent scientist
Mickael Di-Luoffo
Chercheur Post-Doctorant / Post-Doc researcher
Camille Guyon
Doctorant / PhD student
Coralie Cayron
Doctorant / PhD student

PARTERNSHIPS & FUNDING

Centre de Recherches en Cancérologie de Toulouse

Centre de Recherches en Cancérologie de Toulouse (Oncopole)

Toulouse – FR

Nous contacter

05 82 74 15 75

NOUS CONTACTER

Envie de rejoindre
L’équipe du CRCT ?

REJOIGNEZ-NOUS

Pin It on Pinterest